Core Viewpoint - Lantheus Holdings has successfully completed the sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies, allowing the company to concentrate on its PET radiodiagnostics and microbubbles portfolio while advancing its pipeline of radiopharmaceuticals [1] Group 1 - Lantheus has divested its SPECT business, which includes diagnostic agents and manufacturing operations located in North Billerica, Massachusetts, as well as related operations in Canada [1] - The divestiture aligns with Lantheus' strategy to focus on its growing commercial portfolio and enhance its research and development efforts in radiopharmaceuticals [1]